Navigation Links
Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down

Ponte Vedra Beach, Florida (PRWEB) January 17, 2013

The most-read story in HealthEconomics.Com HealthCare Value and Market Access News for the week ending January 12, 2012 examined the annual price tag for Gattex, a treatment for short bowel syndrome, at $295,000 per year. The price was based on Gattex marketer’s analysis of competitors, as well as hospitalization costs avoided. The inpatient cost comparison story will be used with payers, and the company found that patients, physicians, and insurers were willing to pay more than what stock analysts initially predicted. Gattex is an orphan drug, designed to reduce intravenous feedings after resection and partial removal of the small intestine, and is the first drug approved for the treatment of small bowel syndrome since 2004. Recent reports indicate that about 3,000 patients will potentially benefit from such treatment.

Another top story on HealthEconomics.Com explored the record number of 39 drug approvals by the Food & Drug Administration (FDA) in 2012, a level not seen since 1996 when 53 new drugs were approved. FDA has been touting their productivity level for meeting or exceeding nearly all PDUFA goals for application review.    This story is featured on HealthEconomics.Com News on healthcare trends.

Is a buying spree in store for the pharmaceutical industry? Another frequently-read story explored how big pharma is shoring up their bank balances, and their need to fill revenue gaps left by the patent cliff. One solution the industry appears to be pursuing is to buy companies with high-potential drugs in the pipeline, rather than to wait for their own R&D to produce returns. The story is featured on HealthEconomics.Com Pharmaceutical Industry News.

About HealthEconomics.Com: A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and pharma market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.

News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com Pharmaceutical News by visiting the site or by subscribing to the HealthEconomics.Com Newsletter.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
2. HealthEconomics.Com Appoints New Director of Information Technology and Operations
3. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
4. Eckert & Ziegler Vitalea Science and Korea-based BioCore Bring Human Microdosing to Korea to Address the Needs of the Emergent Pharmaceutical Industry
5. Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
6. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
7. BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM360
8. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
9. Asia-Pacific Active Pharmaceutical Ingredients (APIs) Market Analysis & Forecasts to 2017 in New Research Report @
10. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
11. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):